Roivant Sciences Ltd.

Pharmaceutical Preparations·LONDON·FY end 03/31·CIK 1635088

CEO Pay Ratio

518:1

Matthew Gline

CEO Total Comp

$163.3M

Matthew Gline

Median Employee

$315,444

Revenue

$29.1M

FY 2024

Net Income

-$172.0M

FY 2024

Free Cash Flow

-$844.0M

FY 2024

Net Margin

-592.0%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

-94.95%

For every $1,000 of profit, $-949.49 flows to the CEO.

CEO comp as % of buybacks

12.63%

CEO comp equals 126.3‰ of cash returned to shareholders via buybacks.

3-year history · USD

Metric	FY 2024	FY 2023	FY 2022	Trend
Revenue	$29.1M	$124.8M	$55.3M
Gross Profit	—	—	—	—
Operating Income	-$1.0B	$4.2B	-$1.4B
Net Income	-$172.0M	$4.3B	-$845.3M
Operating CF	-$839.5M	-$765.3M	-$677.7M
Capex	$4.6M	$1.4M	$17.4M
Free Cash Flow	-$844.0M	-$766.6M	-$695.2M
Buybacks	$1.3B	—	—	—
Dividends	—	—	—	—

Gross Margin	—	—	—	—
Operating Margin	-3453.3%	3399.2%	-2444.8%
Net Margin	-592.0%	3484.9%	-1528.9%
FCF Margin	-2905.2%	-614.3%	-1257.4%
R&D / Revenue	1894.5%	402.0%	873.7%
Effective Tax	-7.1%	0.5%	-0.0%
Debt / Equity	—	0.07	0.25
Buybacks / FCF	-153.2%	—	—	—

FY 2024

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Mayukh SukhatmePresident and Chief Investment Officer	$550.0K	$170.2M	—	$81.1M	$21.0K	$251.9M
Matthew GlineChief Executive Officer	$725.0K	$157.6M	—	$5.0M	$12.0K	$163.3M
Eric VenkerPresident and Immunovant CEO	$600.2K	$2.2M	$2.9M	$6.0M	$32.7K	$11.8M
Rakhi KumarFormer Chief Accounting Officer	$370.2K	$412.4K	$1.9M	$1.7M	$398.2K	$4.7M
Richard PulikChief Financial Officer	$437.8K	$410.1K	$2.2M	$1.1M	$1.8K	$4.1M
Jennifer HumesChief Accounting Officer	$41.9K	$1.2M	$826.9K	$281.4K	$1.3K	$2.4M